期刊文献+

固定复合制剂治疗肺结核患者依从性分析 被引量:7

A study on patients’ compliance of fixed-dose combination (FDC) in anti tuberculosis treatment
下载PDF
导出
摘要 目的探讨肺结核患者对固定复合制剂(FDC)治疗的依从性及影响因素。方法选择新发涂阳肺结核患者373例,其中FDC组232例,对照组141例,并对治疗期间的患者进行问卷调查。结果46.0%FDC组患者认为药片数合适,51.2%认为药片大小合适,均高于对照组患者(21.9%与34.4%)(P<0.05)。与对照组相比,更多的FDC组患者认为服药方式可以接受的比例(96.9%)高于组合药(82.4%),两者间差异具有统计学意义(P<0.05)。两组吞服时,药片粘喉、苦味方面没有显著性差异。FDC组的AST异常率(33.3%)比对照组高(20.0%),而TBIL的异常率(6.2%)比对照组低(15.4%)(P<0.05);FDC组的治愈率(93.1%)比对照组高(86.0%)(P<0.05)。结论相对于对照组药物,患者对FDC的依从性更好。 ObjectiveTo evaluate patients' compliance and effective factors of Fixed dose Combination (FDC) in anti tuberculosis therapy. Methods374 cases who were diagnosed as new smear positive pulmonary tuberculosis were allocated into two groups: FDC treatment group (n=232),and control group(n=141).The side effect of that were strictly supervised by doctor. Results51.2% and 46.0%of FDC group thought the size and number of pills were suitable,and 96.9% of FDC group accepted the procedure of taking medicine (P< 0.05 ). But there were almost no difference between two groups in deglutition of pills, bitter and pills' viscidity in throat.No significant difference could be found between two groups about adverse reactions. From laboratory test result:Abnormity rate of AST in FDC group (33.3%)was higher than in controlled group(20.0%), and Abnormity rate of TBIL in FDC group (6.2%)was lower than in FDC group(15.4%) (P<0.05).The distribution of ALT, AST, TBIL was consistent in patients of abnormal test result of hepatic function in two groups.The cure rate of FDC group (93.1%)was higher than that of controlled group(86.0%).ConclusionsFDC can improve compliance of patients in anti tuberculosis therapy.
出处 《中国行为医学科学》 CAS CSCD 2005年第6期535-536,546,共3页 Chinese Journal of Behavioral Medical Science
基金 深圳市科学技术委员会资助项目(200304209)
  • 相关文献

参考文献5

  • 1Bjorn Blomberg, Sergio Spinaci, Bernard Fourie,et al. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis.Bulletin of the World Health Organization, 2001, 79 (1):61-68.
  • 2Hong Kong Chest Service/BMRC. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three times weekly antituberculosis chemotherapy. Am Rev Respir Dis,1989, 64: 36.
  • 3Chaulet P, Boulahbal F. Clinical trial of a combination of three drugs in fixed proportions for the treatment of tuberculosis. Tuberculosis and Lung Disease, 1995, 76: 407-412.
  • 4Ohno M, Yamaguchi I, Yamamoto I, et. al. Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP-induced hepatotoxicity . Intl J of Tuberc Lung Dis,2000,4(3):256-261.
  • 5朱莉贞,严碧涯,马伟路,叶志中,张晨曦,陈志铨,苑松林,钟济和,夏祥新,黄建生,聂玉生,程杰.固定剂量复合剂卫非特/卫非宁治疗结核病的临床对照研究[J].中华结核和呼吸杂志,1998,21(11):645-647. 被引量:33

共引文献32

同被引文献78

引证文献7

二级引证文献144

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部